Rare diseases Marathon sells Duchenne drug to PTC PTC says it will make changes to the price after abandoned launch last month.
News Sarepta files controversial Duchenne drug in EU US biotech seeks conditional approval for eteplirsen in EU.
News PTC's muscular dystrophy drug can stay on EU market - regula... But PTC must conduct further trial to confirm Translarna's benefits.
News Europe delays review of PTC's Duchenne drug Review of marketing authorisation delayed, new trial likely.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
